Though an intravenous infusion of α1AT is used to treat α1ATD patients with lung diseases [1,5], this therapy does not mitigate liver damage and most patients still require liver transplantation [5,6]. This evidence concerns the gene SERPINA1 and alpha 1-antitrypsin deficiency.